^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PMS2 mutation

i
Other names: PMS2, PMS1 Homolog 2, Mismatch Repair System Component, PMS1 Homolog 2, Mismatch Repair Protein, Mismatch Repair Endonuclease PMS2, DNA Mismatch Repair Protein PMS2, PMS1 Protein Homolog 2, PMSL2, PMS2 Postmeiotic Segregation Increased 2, Postmeiotic Segregation Increased 2 Nirs Variant 6, PMS2 Postmeiotic Segregation Increased 2, HNPCC4, PMS2CL, MLH4
Entrez ID:
Related biomarkers:
Phase N/A
Seoul National University Bundang Hospital
Active, not recruiting
Last update posted :
12/06/2022
Initiation :
03/01/2015
Primary completion :
01/30/2021
Completion :
12/01/2023
EGFR • PD-L1 • BRAF • KRAS • TP53 • MSI • MLH1 • MSH6 • MSH2 • PMS2 • RUNX3 • IL1B • NLRP3 • NEUROG1
|
PD-L1 expression • TP53 mutation • KRAS mutation • EGFR mutation • MSI-H/dMMR • BRAF mutation • EGFR expression • PMS2 mutation • TP53 expression • PD-L1 mutation
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
12/02/2022
Initiation :
09/12/2017
Primary completion :
04/02/2024
Completion :
04/02/2024
MLH1 • MSH6 • MSH2 • CD4
|
MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation • MSH6 expression
|
Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • 5-fluorouracil • Cotellic (cobimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
Mayo Clinic
Not yet recruiting
Last update posted :
12/01/2022
Initiation :
12/15/2022
Primary completion :
04/01/2025
Completion :
04/01/2026
MLH1 • MSH6 • MSH2 • EPCAM
|
MSH2 mutation • MLH1 mutation • PMS2 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2a
M.D. Anderson Cancer Center
Not yet recruiting
Last update posted :
11/28/2022
Initiation :
11/25/2023
Primary completion :
11/30/2025
Completion :
11/30/2025
MSI • MLH1 • MSH6 • MSH2
|
MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • aspirin • naproxen
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
11/23/2022
Initiation :
09/19/2022
Primary completion :
07/31/2025
Completion :
07/31/2025
BRAF • MSI • MLH1 • MSH6 • MSH2
|
BRAF mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • NOUS-209
Phase N/A
Dana-Farber Cancer Institute
Active, not recruiting
Last update posted :
11/22/2022
Initiation :
05/08/2019
Primary completion :
12/12/2022
Completion :
12/31/2027
TP53 • BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • APC • EPCAM
|
TP53 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • APC mutation • MSH2 mutation • PMS2 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
George Zogopoulos
Recruiting
Last update posted :
11/04/2022
Initiation :
03/12/2012
Primary completion :
01/01/2025
Completion :
01/01/2025
BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1
|
ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
10/28/2022
Initiation :
06/20/2019
Primary completion :
06/01/2023
Completion :
06/01/2023
MLH1 • MSH6 • MSH2 • EPCAM
|
MSH2 mutation • MLH1 mutation • PMS2 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
Nuvance Health
Recruiting
Last update posted :
10/13/2022
Initiation :
11/01/2016
Primary completion :
11/01/2026
Completion :
11/01/2026
BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • PMS2 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
National Cancer Institute (NCI)
Withdrawn
Last update posted :
09/12/2022
Initiation :
01/28/2021
Primary completion :
06/21/2022
Completion :
06/21/2022
TMB • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3
|
MSI-H/dMMR • POLD1 mutation • MSH2 mutation • PMS2 mutation • EPCAM expression • MSH6 expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
07/13/2022
Initiation :
04/04/2018
Primary completion :
12/21/2023
Completion :
12/21/2023
MSI • MLH1 • MSH6 • MSH2 • EPCAM
|
MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
Renmin Hospital of Wuhan University
Recruiting
Last update posted :
07/13/2022
Initiation :
07/01/2022
Primary completion :
07/01/2023
Completion :
07/30/2023
BRCA1 • BRCA2 • STK11 • MLH1 • MSH6 • MSH2 • EPCAM
|
BRCA1 mutation • STK11 mutation • PALB2 mutation • MSH2 mutation • PMS2 mutation
Phase 1
M.D. Anderson Cancer Center
Recruiting
Last update posted :
06/15/2022
Initiation :
04/18/2017
Primary completion :
04/18/2023
Completion :
04/18/2023
ER • PGR • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1
|
BRCA2 mutation • BRCA1 mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation • BARD1 mutation • RAD51 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
The Hospital for Sick Children
Active, not recruiting
Last update posted :
05/19/2022
Initiation :
05/15/2017
Primary completion :
09/01/2022
Completion :
09/01/2022
TMB • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3 • EPCAM • APOB
|
MSI-H/dMMR • POLE mutation • POLD1 mutation • MSH2 mutation • PMS2 mutation • EPCAM expression
|
Opdivo (nivolumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
University of Washington
Recruiting
Last update posted :
05/16/2022
Initiation :
05/21/2020
Primary completion :
08/31/2023
Completion :
08/31/2023
TP53 • BRCA1 • BRCA2 • ATM • MLH1 • MSH6 • MSH2 • CHEK2 • HOXB13
|
PALB2 mutation • CHEK2 mutation • PMS2 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Fox Chase Cancer Center
Recruiting
Last update posted :
04/07/2022
Initiation :
09/10/2018
Primary completion :
09/01/2022
Completion :
09/10/2023
MLH1 • MSH6 • MSH2 • CASP3 • EPCAM
|
MSH2 mutation • MLH1 mutation • PMS2 mutation
|
atorvastatin • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
03/02/2022
Initiation :
02/01/2015
Primary completion :
02/01/2024
Completion :
02/01/2024
STK11 • MLH1 • MSH6 • SMAD4 • MSH2 • APC • EPCAM • BMPR1A
|
MSH2 mutation • MLH1 mutation • PMS2 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
Mayo Clinic
Recruiting
Last update posted :
12/30/2021
Initiation :
12/11/2019
Primary completion :
12/01/2025
Completion :
12/01/2026
TP53 • BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • APC • EPCAM
|
TP53 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • APC mutation • MSH2 mutation • PMS2 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
Massachusetts General Hospital
Recruiting
Last update posted :
12/15/2021
Initiation :
02/12/2020
Primary completion :
12/01/2030
Completion :
12/01/2040
TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD51D • EPCAM • NBN • HOXB13 • GEN1
|
CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • PMS2 mutation • NBN mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
Fujian Cancer Hospital
Not yet recruiting
Last update posted :
11/23/2021
Initiation :
12/01/2021
Primary completion :
05/01/2023
Completion :
05/01/2023
MLH1 • MSH6 • MSH2 • EPCAM
|
MSH2 mutation • MLH1 mutation • PMS2 mutation • MLH3 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
Beth Israel Deaconess Medical Center
Recruiting
Last update posted :
08/16/2021
Initiation :
07/10/2020
Primary completion :
07/10/2025
Completion :
07/10/2026
BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • BRCA • EPCAM • PRSS1
|
BRCA2 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS2 mutation • BRCA mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
White Plains Hospital
Recruiting
Last update posted :
03/12/2021
Initiation :
04/01/2014
Primary completion :
03/01/2024
Completion :
03/01/2024
BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1
|
TP53 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
01/25/2021
Initiation :
01/27/2014
Primary completion :
10/25/2019
Completion :
01/05/2021
MSI • MLH1 • MSH6 • MSH2
|
MSI-H/dMMR • MLH1 mutation • PMS2 mutation
|
naproxen
Phase 1/2
Asan Medical Center
Unknown status
Last update posted :
12/03/2019
Initiation :
06/11/2018
Primary completion :
06/30/2021
Completion :
06/30/2021
PD-L1 • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3 • PMS1 • POLD2
|
MSI-H/dMMR • PD-L1 amplification • POLD1 mutation • MSH2 mutation • MLH1 mutation • MSH3 mutation • PMS2 mutation • MLH3 mutation • PMS1 mutation • POLD2 mutation
|
Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
Medical University Innsbruck
Unknown status
Last update posted :
11/28/2018
Initiation :
01/01/2019
Primary completion :
01/01/2021
Completion :
01/01/2021
NF1
|
NF1 mutation • PMS2 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
M.D. Anderson Cancer Center
Recruiting
Last update posted :
12/12/2017
Initiation :
01/01/2014
Primary completion :
01/01/2021
MSI • MLH1 • MSH6 • MSH2
|
MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation
|
naproxen
Phase N/A
Rabin Medical Center
Unknown status
Last update posted :
10/17/2017
Initiation :
02/01/2014
Primary completion :
06/01/2018
Completion :
06/01/2019
BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRCA
|
BRCA2 mutation • BRCA1 mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation • BRCA mutation
Phase N/A
Wageningen University
Recruiting
Last update posted :
10/06/2017
Initiation :
07/01/2006
Primary completion :
12/01/2030
Completion :
12/01/2030
MLH1 • MSH6 • MSH2 • EPCAM
|
MSH2 mutation • MLH1 mutation • PMS2 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Rabin Medical Center
Not yet recruiting
Last update posted :
09/20/2017
Initiation :
08/01/2016
Primary completion :
07/01/2022
Completion :
07/01/2022
MLH1 • MSH6 • MSH2
|
MSH2 mutation • MLH1 mutation • PMS2 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)